Subcutaneous Infliximab May Boost Crohn's Remission Rates
A study shows subcutaneous delivery may improve remission for adults with ileal Crohn's disease.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Do you trust newer drug delivery methods more than traditional hospital-administered IV treatments for chronic conditions?
Subcutaneous infliximab achieved higher rates of clinical and endoscopic remission in patients with ileal Crohn's disease compared to intravenous treatment by week 54. These findings, presented at the American College of Gastroenterology meeting in Nashville, offer new insight for individuals managing this chronic condition.
Why it matters
Choosing the right delivery method for biologic therapy is critical for managing ileal Crohn's disease, as higher remission rates may improve long-term outcomes and gut healing. Researchers conducted this analysis to determine if patients see better results with one administration route over another.
In a matched analysis of 140 patients from four trials, researchers found that subcutaneous infliximab led to higher clinical and endoscopic remission rates at week 54 compared to IV administration. Because these findings are based on retrospective matching rather than a direct head-to-head trial, the results remain preliminary.
The players
American College of Gastroenterology
A professional medical society for physicians and scientists that specializes in the diagnosis and treatment of digestive disorders.
The details
Infliximab is a biologic medication that works by blocking a protein called TNF-alpha, which contributes to inflammation in the intestinal lining. The study compared the traditional intravenous infusion of 5 mg/kg every 8 weeks against a subcutaneous delivery of 120 mg every 2 weeks. Results indicated that maintaining higher, consistent serum concentrations of the drug may be linked to improved endoscopic responses in the gut.
Timeline
Week 54: Clinical and endoscopic outcomes were measured.
Health Landscape
This research contributes to the ongoing development of biologic maintenance therapies for inflammatory bowel disease by evaluating delivery-route efficacy. It highlights a shift in focus toward optimizing drug administration to achieve deeper healing beyond simple symptom control.
If you are currently prescribed infliximab for Crohn's disease, you may want to ask your gastroenterologist about the potential benefits of different delivery methods. This is a conversation to have with your care team to determine if a change in administration is appropriate for your specific treatment plan.
The takeaway
Higher drug concentration through consistent subcutaneous delivery may lead to improved gut healing for those with ileal Crohn's disease. As clinical options evolve, keep a record of your current symptoms and treatment intervals to share with your physician at your next follow-up.
Further reading
For more information on managing the dietary and medical aspects of digestive health, see our Nutrition section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust newer drug delivery methods more than traditional hospital-administered IV treatments for chronic conditions?
